How To Pay For AMR Drugs: Pull, Not Just Push
Encouraging companies to develop new antimicrobials requires a new way of thinking about value assessment. A UK five-year AMR plan takes this into consideration.
You may also be interested in...
The Council of the EU has published its conclusions on making the EU a “best practice region” in combatting antimicrobial resistance. While there are plenty of recommendations, little concrete action is proposed.
There has been an enthusiastic response from industry to the news that NICE and NHS England are to explore a new payment model that pays pharmaceutical companies based on how valuable their medicines are to the country's health service, rather than on the quantity of antibiotics sold.
Patient access schemes have helped the Scottish Medicines Consortium recommend rare disease products, including Regeneron/Sanofi’s Libtayo for skin cancer.